ES2098485T3 - Complejo que contiene el factor de coagulacion ix. - Google Patents

Complejo que contiene el factor de coagulacion ix.

Info

Publication number
ES2098485T3
ES2098485T3 ES92890018T ES92890018T ES2098485T3 ES 2098485 T3 ES2098485 T3 ES 2098485T3 ES 92890018 T ES92890018 T ES 92890018T ES 92890018 T ES92890018 T ES 92890018T ES 2098485 T3 ES2098485 T3 ES 2098485T3
Authority
ES
Spain
Prior art keywords
coagulation factor
complex containing
factor
plasmazimogeno
hydrophoba
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES92890018T
Other languages
English (en)
Inventor
Yendra Dr Linnau
Maria Dipl-Ing Sazgary
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oesterreichisches Institut fuer Haemoderivate
Original Assignee
Immuno AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immuno AG filed Critical Immuno AG
Application granted granted Critical
Publication of ES2098485T3 publication Critical patent/ES2098485T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/644—Coagulation factor IXa (3.4.21.22)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21022—Coagulation factor IXa (3.4.21.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Measurement Of Velocity Or Position Using Acoustic Or Ultrasonic Waves (AREA)
  • Separation Of Suspended Particles By Flocculating Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Compounds Of Unknown Constitution (AREA)

Abstract

EL FACTOR IX ES ABSORBIDO MEDIANTE CROMATOGRAFIA HIDROFOBA DE FORMA SELECTIVA DE UNA MEZCLA ACUOSA, LA CUAL, JUNTO CON EL FACTOR IX, CONTIENE TODAVIA AL MENOS UN PLASMAZIMOGENO O UNA VITAMINA PROTEINA DEPENDIENTE DE K. ESTE METODO HACE POSIBLE UNA CONCENTRACION EFICAZ DEL FACTOR IX PARA LA FABRICACION DE PREPARADOS FARMACEUTICOS.
ES92890018T 1991-01-25 1992-01-23 Complejo que contiene el factor de coagulacion ix. Expired - Lifetime ES2098485T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AT0016391A AT402261B (de) 1991-01-25 1991-01-25 Komplex enthaltend den gerinnungsfaktor ix

Publications (1)

Publication Number Publication Date
ES2098485T3 true ES2098485T3 (es) 1997-05-01

Family

ID=3483232

Family Applications (1)

Application Number Title Priority Date Filing Date
ES92890018T Expired - Lifetime ES2098485T3 (es) 1991-01-25 1992-01-23 Complejo que contiene el factor de coagulacion ix.

Country Status (12)

Country Link
US (2) US5281661A (es)
EP (1) EP0496725B1 (es)
JP (2) JP2651307B2 (es)
AT (2) AT402261B (es)
CA (1) CA2059979C (es)
CZ (2) CZ154794A3 (es)
DE (1) DE59207638D1 (es)
DK (1) DK0496725T3 (es)
ES (1) ES2098485T3 (es)
FI (1) FI100111B (es)
HU (1) HU212362B (es)
SK (2) SK280989B6 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2105282C (en) 1991-03-01 2002-09-24 Centeon L.L.C. Preparation of factor ix
DE4342132C1 (de) * 1993-12-10 1994-11-03 Octapharma Ag Verfahren zur Herstellung virusinaktivierte Vitamin K abhängige Plasmakomponenten sowie Protein C und Protein S enthaltender Mittel durch Membran-Chromatographie
EP0716744B1 (en) * 1994-06-30 2001-11-07 Dade Behring Inc. Bioactive porous partition members
US5602037A (en) * 1994-06-30 1997-02-11 Dade International, Inc. Combination reagent holding and test device
US5888826A (en) * 1994-06-30 1999-03-30 Dade Behring Inc. Combination reagent holding and test device
DE19506633A1 (de) * 1995-02-25 1996-08-29 Octapharma Ag Verfahren zur Herstellung von Faktor IX aus biologischen Quellen
US5714583A (en) 1995-06-07 1998-02-03 Genetics Institute, Inc. Factor IX purification methods
US5958716A (en) * 1996-06-06 1999-09-28 Dade Behring Inc. Blood factor assay
CN1284881A (zh) * 1997-11-05 2001-02-21 吉富制药株式会社 肝素辅助因子ⅱ制剂及其制备方法
JP4855074B2 (ja) * 2003-09-30 2012-01-18 一般財団法人化学及血清療法研究所 高純度血液凝固ｉｘ因子調製物およびその精製方法
CA2571292C (en) 2004-06-30 2013-05-21 Nektar Therapeutics Al, Corporation Polymer-factor ix moiety conjugates
JP2008525381A (ja) * 2004-12-23 2008-07-17 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 関心のあるビタミンｋ依存性タンパク質を含んでなる組成物中におけるタンパク質混入物の量の減少
MY157239A (en) 2009-05-27 2016-05-13 Baxalta Inc A method to produce a highly concentrated immunoglobulin preparation for subcutaneous use
CN102655853B (zh) 2009-09-17 2015-07-29 巴克斯特卫生保健有限公司 透明质酸酶和免疫球蛋白的稳定的复合制剂及其使用方法
EA032336B1 (ru) 2010-09-17 2019-05-31 Баксалта Инкорпорейтид Стабильная водная иммуноглобулиновая композиция и способ стабилизации иммуноглобулиновой композиции
AU2011343813B2 (en) 2010-12-15 2015-05-21 Takeda Pharmaceutical Company Limited Eluate collection using conductivity gradient
WO2012154272A1 (en) 2011-02-25 2012-11-15 Wellstat Diagnostics, Llc Assays for detecting enzymatic activity
CN121985959A (zh) 2023-09-26 2026-05-05 武田药品工业株式会社 耗减IgA的免疫球蛋白制剂

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2543448A1 (fr) * 1983-04-01 1984-10-05 Rhone Poulenc Spec Chim Procede de fractionnement du plasma
US4820805A (en) * 1983-07-14 1989-04-11 New York Blood Center, Inc. Undenatured virus-free trialkyl phosphate treated biologically active protein derivatives
AT389815B (de) * 1984-03-09 1990-02-12 Immuno Ag Verfahren zur inaktivierung von vermehrungsfaehigen filtrierbaren krankheitserregern in blutprodukten
US4721572A (en) * 1985-07-12 1988-01-26 Miles Laboratories, Inc. Purfication of blood clotting factors and other blood proteins on non-carbohydrate sulfated matrices
ATE130620T1 (de) * 1986-01-06 1995-12-15 Blood Systems Inc Therapeutisches blutprodukt, mittel und verfahren zu dessen erzeugung.
JPS63108000A (ja) * 1986-05-15 1988-05-12 Green Cross Corp:The 第８因子の精製方法
US4725673A (en) * 1986-08-29 1988-02-16 Alpha Therapeutic Corporation Plasma fraction purification using silica resin bound to a ligand
EP0317376B2 (fr) * 1987-10-23 1996-04-03 Centre Regional De Transfusion Sanguine De Lille Préparation de concentré de facteur IX humain de haute pureté et d'autres protéines plasmatiques
DE3914869C1 (es) * 1989-05-05 1990-08-09 Biotest Pharma Gmbh, 6072 Dreieich, De

Also Published As

Publication number Publication date
HUT63863A (en) 1993-10-28
SK280989B6 (sk) 2000-10-09
JPH08259449A (ja) 1996-10-08
JP2866047B2 (ja) 1999-03-08
CZ280297B6 (cs) 1995-12-13
ATE146220T1 (de) 1996-12-15
JP2651307B2 (ja) 1997-09-10
US5409990A (en) 1995-04-25
CA2059979C (en) 2003-04-15
FI920342A0 (fi) 1992-01-24
SK280130B6 (sk) 1999-08-06
EP0496725A3 (en) 1993-05-05
US5281661A (en) 1994-01-25
ATA16391A (de) 1996-08-15
EP0496725B1 (de) 1996-12-11
AT402261B (de) 1997-03-25
FI100111B (fi) 1997-09-30
JPH04295432A (ja) 1992-10-20
CA2059979A1 (en) 1992-07-26
DE59207638D1 (de) 1997-01-23
HU9200225D0 (en) 1992-04-28
DK0496725T3 (da) 1997-06-09
CZ280725B6 (cs) 1996-04-17
CS21192A3 (en) 1992-08-12
FI920342L (fi) 1992-07-26
CZ154794A3 (en) 1996-04-17
EP0496725A2 (de) 1992-07-29
HU212362B (en) 1996-06-28

Similar Documents

Publication Publication Date Title
ES2079063T3 (es) Utilizacion de analogos de vitamina d en el tratamiento del acne.
ES2052495T3 (es) Terapia de fluidos con aniones l-lactato y/o piruvato.
ES2053510T3 (es) Analogos de rebecamicina.
CR7583A (es) Nueva sal formiato de o-desmetil venlafaxina
SV1995000045A (es) Benzoxazolil- y benzotiazoliloxazolidinonas, ref. le a 30616-sv
MX9206817A (es) Nuevos azoheterociclilmetil-cromanos, procedimiento para su obtencion y medicamento que los contiene.
FI925615A0 (fi) Stabiliserade farmaceutiska kompositioner, som innehaoller en hmg-coa-reduktas-inhibitorfoerening
FI863659A7 (fi) Korkeapaineinen elohopeahöyrypurkauslamppu.
AR025052A1 (es) Derivados de 2-dialquilaminoalquilbifenilo sustituidos, procedimiento para su preparacion, medicamentos que contienen estos compuestos y el uso de estoscompuestos para la preparacion de medicamentos.
KR890015742A (ko) 이병치료용 국소 제제
NO860548L (no) Elektronstyrt bryter med radiell geometri, som anvender tr ¨d-ione-plasma elektronkilde.
ECSP034531A (es) Derivados sustituidos de c-ciclohexilmetilamina
AR030662A1 (es) Beta-tio-alfa-aminoacidos, procedimiento para su fabricacion, medicamentos que contienen estos compuestos y el uso de los tioaminoacidos para la preparacion de medicamentos
ES2166900T3 (es) Derivados de ara-c.
FI886027L (fi) Gasspolsten.
ES2031376T3 (es) Procedimiento para la preparacion de cloruro ferrico a partir de cloruro ferroso.
ECSP034530A (es) Derivados de 6-metil-tramadol sustituido en o
DE3670926D1 (de) Niederdrucknatriumentladungslampe.
NL185481C (nl) Lagedruknatriumdampontladingslamp.
FI821324A0 (fi) Oxazolderivat
DE50204475D1 (de) Präparationen von vitamin e in kombination mit afamin
ES2085051T3 (es) Usos de 1,1,1,3,3,3-hexafluoropropano.
ES2095479T3 (es) Procedimiento para la obtencion del 8,12-oxido-13,14,15,16-tetranorlabdano.
NL7611993A (nl) Lagedruknatriumdampontladingslamp.
ES198629Y (es) Farola de alumbrado, perfeccionada.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 496725

Country of ref document: ES